Project 2: Chemoprevention of pancreatic cancer with lipid-lowering and antidiabetic agents

项目2:降脂和抗糖尿病药物化学预防胰腺癌

基本信息

项目摘要

PROJECT SUMMARY Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human diseases. The focus of research, which had been placed mostly on development of therapeutic agents, has shifted gradually towards its prevention. In this context, many studies have linked obesity and long-standing type-2 diabetes mellitus with PDAC development. These metabolic diseases are characterized by peripheral insulin resistance, hyperinsulinemia, increased IGF-1 and chronic inflammation. Previously, crosstalk mechanisms between insulin/IGF-1 receptors, G protein-coupled receptor (GPCR) and EGF receptor (EGFR) signaling systems have been identified that potently stimulate proliferation of PDAC cells harboring a KRAS mutations. Mitogenic crosstalk depended on the function of mTORC1, ERK and PKD and opposed by AMPK, a target for the antidiabetic agent metformin. The identification of the key downstream targets of this signaling network is of fundamental significance and major translational interest. The YAP/TAZ transcriptional co-activators are emerging as points of integration in the action of KRAS, GPCRs and AMPK, all signaling pathways highly relevant in PDAC. New preliminary studies demonstrate that YAP/TAZ activation is a crucial point of convergence in the crosstalk between GPCR and insulin signaling in PDAC cells. Importantly, lipid-lowering drugs of the statin family potently blocked YAP/TAZ activity, including YAP/TAZ/TEAD-regulated genes, such as CTGF, Cyr61 and NUAK2. Lipophilic statins, including cerivastatin, simvastatin and atorvastatin, strikingly inhibited colony formation of human and mouse PDAC cells. Statins inhibited PDAC colony formation acting synergistically with metformin. Further preliminary results in vivo show that oral administration of simvastatin attenuated the loss of intact acini and the development of pre-neoplastic lesions in the pancreas promoted by an obesogenic diet in conditional KrasG12D (KC) mice. Accordingly, the central hypothesis to be explored in Project 2 of this P01 is that the well tolerated cholesterol-lowering drugs of the statin family inhibit obesity-induced promotion of PDAC via inhibition of PKD/YAP/TAZ. The Specific Aims of Project 2 have been designed to investigate important gaps in current knowledge: 1) Characterize the chemopreventive effects of statins on the progression of PanINs and development of PDAC using the conditional KrasG12D model (KC mice) subjected to control or diet-induced obesity (DIO) and in KC mice carrying a homozygous deletion of the ob gene. 2) Identify a novel molecular mechanism by which statins inhibit YAP/TEAD signaling in mouse and human pancreatic cells. 3) Characterize the inhibitory effect of a low-dose combination of statin and metformin on the development of PDAC: a novel chemopreventive strategy. The studies proposed in Project 2 of this P01 will provide mechanisms and rationale for novel chemo-preventive strategies in obesity-related PDAC. Since statins and metformin are widely used Food and Drug Administration (FDA)-approved drugs, the mechanistic and preclinical studies proposed have the potential for rapid translation to PDAC and other obesity-associated cancers.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JUAN ENRIQUE ROZENGURT其他文献

JUAN ENRIQUE ROZENGURT的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JUAN ENRIQUE ROZENGURT', 18)}}的其他基金

Project 2: Chemoprevention of pancreatic cancer with lipid-lowering and antidiabetic agents
项目2:降脂和抗糖尿病药物化学预防胰腺癌
  • 批准号:
    10605232
  • 财政年份:
    2020
  • 资助金额:
    $ 23.84万
  • 项目类别:
Identification of the growth-promoting PKD/YAP axis as a novel target for the statins in intestinal epithelial cells.
鉴定促生长 PKD/YAP 轴作为肠上皮细胞中他汀类药物的新靶点。
  • 批准号:
    10266021
  • 财政年份:
    2018
  • 资助金额:
    $ 23.84万
  • 项目类别:
Identification of the growth-promoting PKD/YAP axis as a novel target for the statins in intestinal epithelial cells.
鉴定促生长 PKD/YAP 轴作为肠上皮细胞中他汀类药物的新靶点。
  • 批准号:
    9752221
  • 财政年份:
    2018
  • 资助金额:
    $ 23.84万
  • 项目类别:
PKD1 Signaling and Crosstalk Mechanisms in Intestinal Epithelial Cell Regulation
肠上皮细胞调节中的 PKD1 信号传导和串扰机制
  • 批准号:
    8759319
  • 财政年份:
    2014
  • 资助金额:
    $ 23.84万
  • 项目类别:
PKD1 Signaling and Crosstalk Mechanisms in Intestinal Epithelial Cell Regulation
肠上皮细胞调节中的 PKD1 信号传导和串扰机制
  • 批准号:
    9126548
  • 财政年份:
    2014
  • 资助金额:
    $ 23.84万
  • 项目类别:
PKD1 Signaling and Crosstalk Mechanisms in Intestinal Epithelial Cell Regulation
肠上皮细胞调节中的 PKD1 信号传导和串扰机制
  • 批准号:
    8915687
  • 财政年份:
    2014
  • 资助金额:
    $ 23.84万
  • 项目类别:
Chemoprevention of pancreatic cancer witli antidiabetic agents
使用抗糖尿病药物化学预防胰腺癌
  • 批准号:
    8561428
  • 财政年份:
    2013
  • 资助金额:
    $ 23.84万
  • 项目类别:
Calcium-sensing receptor signaling in the regulation of colonic epithelial cells
钙敏感受体信号传导在结肠上皮细胞的调节中
  • 批准号:
    8510389
  • 财政年份:
    2012
  • 资助金额:
    $ 23.84万
  • 项目类别:
Chemoprevention of pancreatic cancer witli antidiabetic agents
使用抗糖尿病药物化学预防胰腺癌
  • 批准号:
    8373906
  • 财政年份:
    2012
  • 资助金额:
    $ 23.84万
  • 项目类别:
Calcium-sensing receptor signaling in the regulation of colonic epithelial cells
钙敏感受体信号传导在结肠上皮细胞的调节中
  • 批准号:
    8970680
  • 财政年份:
    2012
  • 资助金额:
    $ 23.84万
  • 项目类别:

相似海外基金

Deciphering the role of adipose tissue in common metabolic disease via adipose tissue proteomics
通过脂肪组织蛋白质组学解读脂肪组织在常见代谢疾病中的作用
  • 批准号:
    MR/Y013891/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.84万
  • 项目类别:
    Research Grant
ESTABLISHING THE ROLE OF ADIPOSE TISSUE INFLAMMATION IN THE REGULATION OF MUSCLE MASS IN OLDER PEOPLE
确定脂肪组织炎症在老年人肌肉质量调节中的作用
  • 批准号:
    BB/Y006542/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.84万
  • 项目类别:
    Research Grant
Activation of human brown adipose tissue using food ingredients that enhance the bioavailability of nitric oxide
使用增强一氧化氮生物利用度的食品成分激活人体棕色脂肪组织
  • 批准号:
    23H03323
  • 财政年份:
    2023
  • 资助金额:
    $ 23.84万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of new lung regeneration therapies by elucidating the lung regeneration mechanism of adipose tissue-derived stem cells
通过阐明脂肪组织干细胞的肺再生机制开发新的肺再生疗法
  • 批准号:
    23K08293
  • 财政年份:
    2023
  • 资助金额:
    $ 23.84万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Canadian Alliance of Healthy Hearts and Minds: Dissecting the Pathways Linking Ectopic Adipose Tissue to Cognitive Dysfunction
加拿大健康心灵联盟:剖析异位脂肪组织与认知功能障碍之间的联系途径
  • 批准号:
    479570
  • 财政年份:
    2023
  • 资助金额:
    $ 23.84万
  • 项目类别:
    Operating Grants
Determinants of Longitudinal Progression of Adipose Tissue Inflammation in Individuals at High-Risk for Type 2 Diabetes: Novel Insights from Metabolomic Profiling
2 型糖尿病高危个体脂肪组织炎症纵向进展的决定因素:代谢组学分析的新见解
  • 批准号:
    488898
  • 财政年份:
    2023
  • 资助金额:
    $ 23.84万
  • 项目类别:
    Operating Grants
A study on the role of brown adipose tissue in the development and maintenance of skeletal muscles
棕色脂肪组织在骨骼肌发育和维持中作用的研究
  • 批准号:
    23K19922
  • 财政年份:
    2023
  • 资助金额:
    $ 23.84万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
A mechanism of lipid accumulation in brown adipose tissue
棕色脂肪组织中脂质积累的机制
  • 批准号:
    10605981
  • 财政年份:
    2023
  • 资助金额:
    $ 23.84万
  • 项目类别:
Obesity and Childhood Asthma: The Role of Adipose Tissue
肥胖和儿童哮喘:脂肪组织的作用
  • 批准号:
    10813753
  • 财政年份:
    2023
  • 资助金额:
    $ 23.84万
  • 项目类别:
Estrogen Signaling in the Ventromedial Hypothalamus Modulates Adipose Tissue Metabolic Adaptation
下丘脑腹内侧区的雌激素信号调节脂肪组织代谢适应
  • 批准号:
    10604611
  • 财政年份:
    2023
  • 资助金额:
    $ 23.84万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了